Why the study?
Does saxagliptin improve survival and glucose tolerance in a murine model of dilated cardiomyopathy?
Does saxagliptin improve survival and glucose tolerance in a murine model of dilated cardiomyopathy?
In a murine model of dilated cardiomyopathy, DPP4 inhibition with saxagliptin improved glucose tolerance but failed to improve survival.
No takes yet. Share an insight, caveat, or question.
Saxagliptin improves glucose tolerance without survival benefit in this model; leaves open DPP-4 inhibition effects in cardiomyopathy.
Vyas et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: